For Healthcare Professionals

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

clipboard-pencil

About the study

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Must have histological or cytological confirmed diagnosis of locally advanced or metastatic adenocarcinoma of the pancreas, which has progressed on or after one line of chemotherapy
  2. ECOG Performance status 0-1
  3. Adequate organ functions
  4. Measurable disease

EXCLUSION CRITERIA

  1. Suspected or known CNS metastasis
  2. Participants with active, known, or suspected autoimmune disease
  3. Uncontrolled or significant cardiovascular disease
  4. Prior exposure to selected immune cell-modulating antibody regimens
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall please email:Email iconEmail Study Center

Study’s details


Contition

Advanced Pancreatic Cancer

Age

18+

Phase

Phase 2

Participants needed

202

Est. Completion Date

Oct 2023

Treatment type

Interventional


Sponsor

Bristol-Myers Squibb

ClinicalTrials.gov identifier

NCT03336216

Study number

CA025006

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.